Bevacizumab Inhibits Breast Cancer-induced Osteolysis, Surrounding Soft Tissue Metastasis, and Angiogenesis in Rats As Visualized by VCT and MRI

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2008 May 14

PMID 18472968

Citations 21

Authors

Tobias Bauerle

Heidegard Hilbig

Sonke Bartling

Fabian Kiessling

Astrid Kersten

Annette Schmitt-Graff

Hans-Ulrich Kauczor

Stefan Delorme

Martin R Berger

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to evaluate the effect of an antiangiogenic treatment with the vascular endothelial growth factor antibody bevacizumab in an experimental model of breast cancer bone metastasis and to monitor osteolysis, soft tissue tumor, and angiogenesis in bone metastasis noninvasively by volumetric computed tomography (VCT) and magnetic resonance imaging (MRI). After inoculation of MDA-MB-231 human breast cancer cells into nude rats, bone metastasis was monitored with contrast-enhanced VCT and MRI from day 30 to day 70 after tumor cell inoculation, respectively. Thereby, animals of the treatment group (10 mg/kg bevacizumab IV weekly, n = 15) were compared with sham-treated animals (n = 17). Treatment with bevacizumab resulted in a significant difference versus control in osteolytic as well as soft tissue lesion sizes (days 50 to 70 and 40 to 70 after tumor cell inoculation, respectively; P < .05). This observation was paralleled with significantly reduced vascularization in the treatment group as shown by reduced increase in relative signal intensity in dynamic contrast-enhanced MRI from days 40 to 70 (P < .05). Contrast-enhanced VCT and histology confirmed decreased angiogenesis as well as new bone formation after application of bevacizumab. In conclusion, bevacizumab significantly inhibited osteolysis, surrounding soft tissue tumor growth, and angiogenesis in an experimental model of breast cancer bone metastasis as visualized by VCT and MRI.

Citing Articles

Non-Invasive Characterization of Experimental Bone Metastasis in Obesity Using Multiparametric MRI and PET/CT.

Gregoric G, Gaculenko A, Nagel L, Popp V, Maschauer S, Prante O Cancers (Basel). 2022; 14(10).

PMID: 35626085 PMC: 9139574. DOI: 10.3390/cancers14102482.

Effects of bevacizumab administration on the hypoxia - induced pulmonary hypertension rat model.

Demir C, Karaman M, Ucan E, Gokmen A, Gurel D, Coker S Turk J Med Sci. 2021; 51(5):2752-2762.

PMID: 34333902 PMC: 8742496. DOI: 10.3906/sag-2101-76.

Multimodal imaging of bone metastases: From preclinical to clinical applications.

Ellmann S, Beck M, Kuwert T, Uder M, Bauerle T J Orthop Translat. 2018; 3(4):166-177.

PMID: 30035055 PMC: 5986987. DOI: 10.1016/j.jot.2015.07.004.

IDK1 is a rat monoclonal antibody against hypoglycosylated bone sialoprotein with application as biomarker and therapeutic agent in breast cancer skeletal metastasis.

Zepp M, Kovacheva M, Altankhuyag M, Westphal G, Berger I, Gather K J Pathol Clin Res. 2018; 4(1):55-68.

PMID: 29416877 PMC: 5783975. DOI: 10.1002/cjp2.88.

The vasculature: a vessel for bone metastasis.

Raymaekers K, Stegen S, van Gastel N, Carmeliet G Bonekey Rep. 2016; 4:742.

PMID: 27217954 PMC: 4859769. DOI: 10.1038/bonekey.2015.111.

References

Jackson A, OConnor J, Parker G, Jayson G . Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res. 2007; 13(12):3449-59. DOI: 10.1158/1078-0432.CCR-07-0238. View

Senan S, Smit E . Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist. 2007; 12(4):465-77. DOI: 10.1634/theoncologist.12-4-465. View

Gauvain K, Garbow J, Song S, Hirbe A, Weilbaecher K . MRI detection of early bone metastases in b16 mouse melanoma models. Clin Exp Metastasis. 2005; 22(5):403-11. PMC: 2726655. DOI: 10.1007/s10585-005-1264-9. View

Weber M, Lee J, Orr F . The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol. 2002; 20(2):299-303. View

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez E . Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357(26):2666-76. DOI: 10.1056/NEJMoa072113. View

Niida S, Kaku M, Amano H, Yoshida H, Kataoka H, Tanne K . Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med. 1999; 190(2):293-8. PMC: 2195572. DOI: 10.1084/jem.190.2.293. View

Ferrara N . VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002; 2(10):795-803. DOI: 10.1038/nrc909. View

Cobleigh M, Langmuir V, Sledge G, Miller K, Haney L, Novotny W . A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003; 30(5 Suppl 16):117-24. DOI: 10.1053/j.seminoncol.2003.08.013. View

Peyruchaud O, Serre C, NicAmhlaoibh R, Fournier P, Clezardin P . Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. J Biol Chem. 2003; 278(46):45826-32. DOI: 10.1074/jbc.M309024200. View

10.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

11.

Kiessling F, Heilmann M, Vosseler S, Lichy M, Krix M, Fink C . Dynamic T1-weighted monitoring of vascularization in human carcinoma heterotransplants by magnetic resonance imaging. Int J Cancer. 2003; 104(1):113-20. DOI: 10.1002/ijc.10913. View

12.

Wetterwald A, van der Pluijm G, Que I, Sijmons B, Buijs J, Karperien M . Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am J Pathol. 2002; 160(3):1143-53. PMC: 1867183. DOI: 10.1016/S0002-9440(10)64934-6. View

13.

Henriquez N, van Overveld P, Que I, Buijs J, Bachelier R, Kaijzel E . Advances in optical imaging and novel model systems for cancer metastasis research. Clin Exp Metastasis. 2007; 24(8):699-705. DOI: 10.1007/s10585-007-9115-5. View

14.

Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P . Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer. 2006; 95(4):506-14. PMC: 2360666. DOI: 10.1038/sj.bjc.6603285. View

15.

Aldridge S, Lennard T, Williams J, Birch M . Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone. Br J Cancer. 2005; 92(8):1531-7. PMC: 2362001. DOI: 10.1038/sj.bjc.6602417. View

16.

Bartling S, Stiller W, Grasruck M, Schmidt B, Peschke P, Semmler W . Retrospective motion gating in small animal CT of mice and rats. Invest Radiol. 2007; 42(10):704-14. DOI: 10.1097/RLI.0b013e318070dcad. View

17.

Guise T, Chirgwin J . Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res. 2003; (415 Suppl):S32-8. DOI: 10.1097/01.blo.0000093055.96273.69. View

18.

Montemurro F, Russo F, Martincich L, Cirillo S, Gatti M, Aglietta M . Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy. Acta Radiol. 2004; 45(1):71-4. DOI: 10.1080/02841850410003374. View

19.

Missbach-Guentner J, Dullin C, Zientkowska M, Domeyer-Missbach M, Kimmina S, Obenauer S . Flat-panel detector-based volume computed tomography: a novel 3D imaging technique to monitor osteolytic bone lesions in a mouse tumor metastasis model. Neoplasia. 2007; 9(9):755-65. PMC: 1993860. DOI: 10.1593/neo.07466. View

20.

Brix G, Semmler W, Port R, Schad L, Layer G, Lorenz W . Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr. 1991; 15(4):621-8. DOI: 10.1097/00004728-199107000-00018. View